Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006229 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 2 study, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 774
- Enrollment target
NCT00006229 is a Phase 2 study that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 774 participants.
The verdict
NCT00006229, a Phase 2 study, has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 774 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG rebimastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 774 participants |
| Start Date | 2000-04-04 |
| Est. Completion | 2009-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006229
The ClinicalTrials.gov registry entry for NCT00006229 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 774 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00006229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006229 about?
NCT00006229 is a clinical study titled "Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to comp...
What is the current status of trial NCT00006229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 774 participants. The study started on 2000-04-04. Estimated completion is 2009-02-10.
What interventions are being tested in trial NCT00006229?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), rebimastat (DRUG).
Who is sponsoring clinical trial NCT00006229?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.